Zydus seeks approval from DCGI for the clinical trials for the COVID antibodies cocktail

Zydus Cadila is the only Indian company that developed a neutralizing monoclonal antibody-based cocktail to treat the Covid-19. Zydus Cadila has sought a national drug controller's permission to initiate the phase 1/3 human clinical trials for the monoclonal antibodies, which will be used to treat the coronavirus. The drug has the potential to neutralize the infection of Covid. The company has announced that the drug is used to cure mild covid disease. The company is now taking approval from the DCGI to undertake clinical trials for the monoclonal antibody-based cocktail. The drug contains two monoclonal antibodies, which mimic the natural antibodies. Listen Now!